Updates in Melanoma

Dermatologic Clinics

Volumn 37, Issue 1, 2019, Pages 73-82

  Tracey, Elisabeth Hamelin ^a   Vij, Alok ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Gene expression profiling; Immunotherapy; Melanoma; Melanoma staging; Skin cancer; Targeted therapy for melanoma

Indexed keywords

BINIMETINIB; COBIMETINIB; DABRAFENIB; DACARBAZINE; IMATINIB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; LYMPH NODE DISSECTION; MELANOMA; OVERALL SURVIVAL; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SECONDARY; SKIN TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CTLA-4 ANTIGEN; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODE EXCISION; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 85056767542     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2018.08.003     Document Type: Review

References (50)

1. American Cancer Society. Statistics for 2016. Available at: www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed June 1, 2018.
2. American Academy of Dermatology. Melanoma fact sheet. Available at: www.aad.org/media/stats/conditions/melanoma-faqs. Accessed June 1, 2018.
3. Wagner, J.D., Gordon, M.S., Chuang, T.Y., et al. Current therapy of cutaneous melanoma. Plast Reconstr Surg 105 (2001), 1774–1799.
4. Sober, A.J., Chuang, T.Y., Duvic, M., et al. Guidelines/outcomes committee. guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 45 (2001), 579–586.
5. Tsao, H., Update on familial cancer syndromes and the skin. J Am Acad Dermatol 42 (2000), 939–969.
6. Amaral, T., Sinnberg, T., Meier, F., et al. The mitogen-activated protein kinase pathway in melanoma part I — Activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer 73 (2017), 85–92.
7. Gershenwald, J.E., Scolyer, R.A., Hess, K.R., et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:6 (2017), 472–492.
8. Skin Cancer Foundation. What is melanoma? Available at: www.skincancer.org/skin-cancer-information/melanoma. Accessed June 1, 2018.
9. Clinical practice guidelines: melanoma. National Comprehensive Cancer Network. Available at: www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed September 10, 2018.
10. Buzzell, R.A., Zitelli, J.A., Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 34 (1996), 798–803.
11. Ali-Salaam, P., Ariyan, S., Lymphatic mapping and sentinel lymph node biopsies. Clin Plast Surg 27 (2000), 421–429.
12. Murtha, T.D., Han, G., Han, D., Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging. Ann Surg Oncol 25:4 (2018), 903–911.
13. Morton, D.L., Thompson, J.F., Cochran, A.J., et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:7 (2014), 599–609.
14. Stiegel, E., Xiong, D., Ya, J., et al. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. J Am Acad Dermatol 78:5 (2018), 942–948.
15. Odom, R.B., James, W.D., Berger, T.G., Melanocytic nevi and neoplasms. James, W.D., Berger, T.G., Elston, D., (eds.) Andrews’ diseases of the skin, 9th edition, 2000, WB Saunders, Philadelphia, 881–889.
16. Novakovic, B., Clark, W.H. Jr., Fears, T.R., et al. Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families. J Am Acad Dermatol 33:4 (1995), 631–636.
17. Greene, M., Clark, W.H. Jr., Tucker, M.A., et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 102 (1985), 458–465.
18. Faries, M.B., Thompson, J.F., Cochran, A.J., et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:23 (2017), 2211–2222.
19. Leiter, U., Stadler, R., Mauch, C., et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet 17:6 (2016), 757–767.
20. McMasters, K.M., Egger, M.E., Edwards, M.J., et al. Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 34:10 (2016), 1079–1086.
21. Wong, S.L., Faries, M.B., Kennedy, E.B., et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol 36:4 (2018), 399–413.
22. Schuitevoerder, D., Heath, M., Cook, R.W., et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol 17:2 (2018), 196–199.
23. Gerami, P., Cook, R.W., Wilkinson, J., et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21:1 (2015), 175–183.
24. Zager, J.S., Gastman, B.R., Leachman, S., et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer, 18(1), 2018, 130.
25. Ferris, L.K., Farberg, A.S., Middlebrook, B., et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol 76:5 (2017), 818–825.
26. Shaikh, W.R., Dusza, S.W., Weinstock, M.A., et al. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst, 108(1), 2015 [pii:djv294].
27. Ming, M.E., Commentary: the quest for an improved risk stratification tool for patients with melanoma. J Am Acad Dermatol 76:5 (2017), 826–828.
28. Gerami, P., Cook, R.W., Russell, M.C., et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72:5 (2015), 780–785.
29. Kosary, C.L., Altekruse, S.F., Ruhl, J., et al. Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer 120 (2014), 3807–3814.
30. Greenhaw, B.N., Zitelli, J.A., Brodland, D.G., Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test. Dermatol Surg, 2018 [Epub ahead of print].
31. Hsueh, E.C., DeBloom, J.E., Lee, J., et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol, 10(1), 2017, 152.
32. Berger, A.C., Davidson, R.S., Poitras, J.K., et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 32:9 (2016), 1599–1604.
33. Farberg, A.S., Glazer, A.M., White, R., et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions. J Drugs Dermatol 16:5 (2017), 428–431.
34. Svoboda, R.M., Glazer, A.M., Farberg, A.S., et al. Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma. J Drugs Dermatol 17:5 (2018), 544–547.
35. Olszanski, A.J., Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 20:4 (2014), 346–356.
36. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
37. Hauschild, A., Grob, J.J., Demidov, L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:9839 (2012), 358–365.
38. Lugowska, I., Koseła-Paterczyk, H., Kozak, K., et al. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 8 (2015), 2251–2259.
39. Ribas, A., Gonzalez, R., Pavlick, A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15:9 (2014), 954–965.
40. Long, G.V., Hauschild, A., Santinami, M., et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:19 (2017), 1813–1823.
41. Wyman, K., Atkins, M.B., Prieto, V., et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:9 (2006), 2005–2011.
42. Ugurel, S., Hildenbrand, R., Zimpfer, A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:8 (2005), 1398–1405.
43. Couzin-Frankel, J., Breakthrough of the year 2013: cancer immunotherapy. Science 342:6165 (2013), 1432–1433.
44. Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
45. Maio, M., Grob, J.J., Aamdal, S., et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33:10 (2015), 1191–1196.
46. Hamid, O., Puzanov, I., Dummer, R., et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer 86 (2017), 37–45.
47. Schachter, J., Ribas, A., Long, G.V., et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:105 (2017), 1853–1862.
48. Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
49. Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
50. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.